MSB 2.98% $1.47 mesoblast limited

banter and General Discussion, page-11478

  1. 162 Posts.
    lightbulb Created with Sketch. 48
    Hey bud,
    Funny you bring that up. While there hasn’t been a specific ASX announcement solely about a granted patent for the potency assay, Mesoblast has been quite transparent in their regulatory updates, particularly in their September 2023 announcement. Not every patent needs to be blasted out unless it’s price-sensitive or required—standard biotech practice, really. But if you’re still looking for something to nitpick, maybe try reading the actual updates instead of assuming something’s being hidden.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.